International Myeloma Society Accepts Telo Genomics' MRD Abstract for Presentation at Its 2025 Meeting

Core Viewpoint - Telo Genomics' abstract on minimal residual disease (MRD) has been accepted for presentation at the 22nd International Myeloma Society Annual Meeting, highlighting the company's advancements in diagnostic technologies for multiple myeloma [1][3]. Company Summary - Telo Genomics is a leader in developing diagnostic and prognostic tests through telomere analysis, focusing on liquid biopsy applications [1][9]. - The company’s proprietary TeloView MM-MRD technology offers a unique approach to counting and profiling individual MRD cells, providing actionable insights for clinicians regarding relapse risk [3][9]. - Telo Genomics has issued 411,539 common shares to Trusted Health Advisors LLC for services related to the commercialization of its diagnostic technologies, with total compensation of approximately $50,369 (US$36,000) [4]. Industry Summary - The MRD testing market is projected to reach USD 4.1 billion by 2032, driven by advancements in drug development and personalized healthcare [7]. - MRD is defined as the small number of cancer cells remaining post-treatment, and its assessment is crucial for guiding therapeutic decisions in oncology [5][6]. - Multiple myeloma is the second most common blood cancer, with 35,000 new cases annually in the US, and the introduction of next-generation therapies has improved median survival rates to over 5 years [8].